A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2070 Injection

NCT07241923 | Recruiting Phase 1

• 1 other identifier: SYH2070-001
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study of SYH2070 injection when administered subcutaneously to healthy subjects.

Conditions

Healthy Subjects (HS)

Outcome Measures

Primary Outcomes (1)

• Number of Subjects with Adverse Events as Assessed by CTCAE v5.0

  Pre-dose and multiple time points no less than 85 days

Secondary Outcomes (7)

• The serum TG level after dosing SYH2070 injection

  Pre-dose and multiple timepoints no less than 85 days

• The serum LDL-C level after dosing SYH2070 injection

  Pre-dose and multiple timepoints no less than 85 days

• Plasma Maximum concentration (Cmax)

  Pre-dose and multiple timepoints up to 4 days

• Time to maximum concentration (Tmax)

  Pre-dose and multiple timepoints up to 4 days

• Area under the concentration-time curve from 0 to the collection time t (AUC0-t)

  Pre-dose and multiple timepoints up to 4 days

Study Arms (2)

SYH2070 experimental group

EXPERIMENTAL

Subjects in experimental groups will receive a single subcutaneous injection of SYH2070 injection on Day 1.

Drug: SYH2070 injection

Placebo group

PLACEBO COMPARATOR

Subjects in placebo groups will receive a single subcutaneous injection of placebo on Day 1.

Drug: Placebo

Interventions

SYH2070 injection DRUG

subcutaneous injection

SYH2070 experimental group

Placebo DRUG

subcutaneous injection

Placebo group

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subjects must provide informed consent before the trial, fully understand its content, procedures, and potential adverse reactions, and voluntarily sign the written ICF;
• Sex: Male or female;
• Age: 18-60 years (inclusive);
• Body mass index (BMI) in the range of 19 to 30 kg•m\^2 \[BMI = weight/height\^2 (kg•m\^2)\] (inclusive), with a weight of no less than 50 kg for males (inclusive) and no less than 45 kg for females (inclusive);
• Fasting serum TG ≥150 mg/dL (1.7 mmol/L) and ≤ 500 mg/dL (5.6 mmol/L), and LDL-C ≥70 mg/dL (1.8 mmol/L) and \< 190 mg/dL (4.9 mmol/L) during the screening and baseline periods;
• Subjects must maintain stable die, exercise, and other lifestyle habits from 4 weeks prior to screening until the end of the study, with no planned changes to diet, exercise or weight loss programs;
• Subjects must be able to communicate well with the investigator and can complete the study according to the protocol requirements.

You may not qualify if:

• History of severe allergic diseases or allergic constitution (≥ 3 drug or food allergies), or known history of allergy to the investigational drug components (N-acetylgalactosamine, sodium hydroxide, phosphoric acid) or oligonucleotide drugs;
• Use of antibody drugs and/or oligonucleotide drugs targeting PCSK9/ANGPTL3/ApoC-III within 12 months prior to screening;
• Current and/or history of clinically significant medical conditions, including but not limited to circulatory, hematological or hematopoietic, respiratory, endocrine, urinary, digestive system diseases, neurological or psychiatric disorders, infections, tumors, severe trauma, or any other disease that should be excluded or may interfere with the interpretation of the study results, as judged by the investigator;
• History of major surgery within 6 months prior to screening, or are scheduled to undergo major surgery during the course of the study;
• History of bariatric surgery within 12 months prior to screening;
• Have clinically significant abnormalities in vital signs, physical examination, electrocardiogram, and laboratory tests (excluding lipid parameters);
• Estimated glomerular filtration rate (eGFR) \<90 mL/min/1.73 m\^2 at screening;
• Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), gamma-glutamyl transferase (GGT), or alkaline phosphatase (ALP) \>1.5× upper limit of normal (ULN) at screening (one retest allowed within 1 week);
• Prolonged QT / QTc interval at screening or baseline (QTcF \> 450 ms);
• Positive result for any of HBsAg, HCV antibody, syphilis antibody, and HIV antibody;
• Blood loss or donation \>200 mL within 3 months prior to screening (excluding menstruation for females), and/or platelet donation within 2 weeks;
• Use of any drugs, health supplements, vitamins, or dietary supplements known to affect lipid metabolism within the longer of either: (a) 28 days prior to dosing; (b) 7 half-lives of the drug; (3) the duration of the agent's pharmacological effect, including but not limited to statins, fish oil, high-purity omega-3, prescription-dose niacin, fibrates, or anti-estrogen therapy;

Sponsors & Collaborators

• CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.: lead

Study Sites (1)

Clinical Trials Information Group

Shijiazhuang, Hebei, China

RECRUITING

Central Study Contacts

Clinical Trials Information Group officer

CONTACT

+86-0311-69085587; ctr-contact@cspc.cn

Yang Lin

CONTACT

18910778667; linyang@anzhengcp.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 17, 2025
• First Posted: November 21, 2025
• Study Start: November 15, 2025
• Primary Completion (Estimated): November 1, 2026
• Study Completion (Estimated): November 1, 2027
• Last Updated: December 1, 2025

Record last verified: 2025-11

Locations

CN (1)